Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
Teva
Fish and Richardson
Queensland Health
Cerilliant
Fuji
Merck
Healthtrust

Generated: October 17, 2018

DrugPatentWatch Database Preview

Janssen R And D Company Profile

« Back to Dashboard

What is the competitive landscape for JANSSEN R AND D, and when can generic versions of JANSSEN R AND D drugs launch?

JANSSEN R AND D has two approved drugs.

There are four US patents protecting JANSSEN R AND D drugs.

Summary for Janssen R And D
US Patents:4
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Janssen R And D

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Janssen R And D PARAFON FORTE DSC chlorzoxazone TABLET;ORAL 011529-002 Jun 15, 1987 DISCN Yes No ➤ Sign Up ➤ Sign Up
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-003 Mar 26, 2012 RX Yes No 7,887,845*PED ➤ Sign Up Y ➤ Sign Up
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-003 Mar 26, 2012 RX Yes No 7,037,917*PED ➤ Sign Up Y ➤ Sign Up
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-001 Jan 18, 2008 RX Yes No 7,887,845*PED ➤ Sign Up Y ➤ Sign Up
Janssen R And D INTELENCE etravirine TABLET;ORAL 022187-001 Jan 18, 2008 RX Yes No 7,037,917*PED ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Janssen R And D Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0373 Netherlands ➤ Sign Up 300373, 20191101, EXPIRES: 20230827
2009 00004 Denmark ➤ Sign Up
C0004 France ➤ Sign Up PRODUCT NAME: ETRAVIRINE AINSI QUE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/08/468/001 DU 20080828; REGISTRATION NO/DATE AT EEC: EU/1/08/468/001 DU 20080828
C033/2008 Ireland ➤ Sign Up SPC033/2008: 20090914, EXPIRES: 20230827
C/GB09/003 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/003 GRANTED TO JANSSEN PHARMACEUTICA NV IN RESPECT OF THE PRODUCT ETRAVIRINE OPTIONALLY IN A FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6342 DATED 08 DECEMBER 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 AUGUST 2023.
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Boehringer Ingelheim
Colorcon
Mallinckrodt
Cerilliant
Citi
Chubb
Covington
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.